Medicus Pharma has entered a strategic collaboration with the Gorlin Syndrome Alliance to pursue an Expanded Access IND for Skinject, an investigational doxorubicin-containing dissolvable microneedle array for patients with Gorlin syndrome facing multiple, recurrent, or inoperable basal cell carcinomas. The program aims to enable physician-supervised compassionate use while generating real-world safety and tolerability data that could inform future regulatory submissions.
The move elevates expanded access from a patient-support tool to a development lever. If executed well, it could seed a high-quality evidence stream for a device-enabled, localized oncology therapy that targets a uniquely high-burden rare disease population. The strategic question is whether RWE captured in a compassionate-use context—aligned with clinical endpoints and monitoring standards—can meaningfully de-risk Medicus’s potential 505(b)(2) path and catalyze payer readiness for a procedure-sparing intervention in dermatologic oncology.
For patients with Gorlin syndrome—approximately 1 in 31,000 globally—who can experience hundreds to over a thousand BCCs across a lifetime, standard care often means repeated surgeries, scarring, and chronic treatment cycles. A patch-based, in-clinic option that delivers cytotoxic therapy intradermally could shift care from the operating room to the dermatology suite, with potential benefits in cosmesis, convenience, and cumulative healthcare utilization. For dermatologists and Mohs surgeons, adoption would hinge on clear lesion-level control, manageable application workflows, and recurrence data. For payers, the calculus will weigh per-lesion cost against avoided surgeries, facility fees, and downstream complications, making robust health economic analyses essential early in the access journey.
Medicus’s clinical footing is advancing. The company’s randomized, double-blind, triple-arm Phase 2 study (SKNJCT-003) in the United States and Europe expanded to 90 participants following an interim look reported as showing over 60% clinical clearance, with most patients now randomized. FDA Type C feedback indicating a potential 505(b)(2) pathway signals a pragmatic regulatory route for a known cytotoxic agent in a novel delivery format, though device-drug safety, local tolerability, repeat-use effects, and recurrence rates will be scrutinized. A parallel multicenter study in the United Arab Emirates (SKNJCT-004) adds geographic breadth and operational learning but increases the need for harmonized endpoints and data integrity across settings.
Competitive context is nuanced. Hedgehog pathway inhibitors remain a systemic option for advanced BCC but are limited by tolerability over time, particularly in populations requiring chronic control. Topicals and photodynamic therapy address specific subtypes but are often insufficient for the relentless lesion cadence of Gorlin syndrome. A microneedle-delivered anthracycline promises concentrated local effect with potentially lower systemic exposure, yet will require careful monitoring for local necrosis, pigmentary change, and cumulative toxicity. Market adoption could be rapid in specialty centers if outcomes and cosmetic profiles outperform surgery for appropriate lesions, but supply chain reliability and training for standardized application will be the implementation gatekeepers.
The collaboration also underscores broader currents: patient-advocacy partnerships shaping protocol design and access frameworks; RWE increasingly embedded in pre-approval strategies; microneedle drug-device combinations moving from vaccine pilots to oncology use cases; and capital-constrained biotechs leveraging 505(b)(2) to compress timelines. Medicus’s recent acquisition of Antev and its teverelix program in prostate cancer suggests a portfolio hedge across dermatology and urology, aligning with a trend toward diversified, nearer-term assets to balance platform bets.
What to watch next: whether expanded access yields regulator-ready safety signals and payer-relevant outcomes such as lesion clearance durability, cosmetic benefit, and quality-of-life gains—and whether Medicus can convert SKNJCT-003 from exploratory to pivotal. The bigger industry question is whether localized oncology delivery via microneedles becomes a defensible category, or a bridge technology that incumbents in dermatology and oncology quickly emulate with their own device-enabled therapeutics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
